|
|
|
| Outsourced Pharma Capabilities Update | This online event series connects biopharma companies with CDMOs to explore capabilities across biologics production, HPAPI manufacturing, and drug–device combination development. Through concise presentations, CDMOs showcase expertise in development, scale-up, containment, and GMP manufacturing. Attendees gain insights into technologies, regulatory expectations, and partnership models, while engaging directly with providers to evaluate outsourcing options and identify the best-fit partners for advancing and commercializing complex therapies. Click to learn more. |
|
|
|
| Engineering Approaches To Respiratory Drug Delivery | Case Study | By Cameron Kadleck, Jimmy Beaty, Matthew Ferguson, Ph.D., Lonza | Explore the material and performance properties of spray-dried and jet-milled mannitol for respiratory delivery of crystalline mannitol. |
|
|
|
| Silica‑Based Approaches to Better Micronization | Case Study | Grace Fine Chemical Manufacturing Services | Here, we demonstrate how adding small amounts of SYLOID® mesoporous silica to Cholesterol before jet milling can enhance processing efficiency, boost yield, and improve micronization performance. |
|
|
|
|
By Louis Garguilo, chief editor, Outsourced Pharma | GeoVax CEO David Dodd sings the praises and is grateful for the program-enabling relationships he has in Europe. At the same time, he harbors lingering disappointment. From the outset of its formation, the biotech has desired to work with U.S.-based CDMOs. But he says he will not give up. “One way or the other,” Dodd says, “GeoVax will have U.S.-based manufacturing.” | |
|
|
February 2026 — CDMO Opportunities And Threats Report | By GlobalData | Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections. |
|
|
INDUSTRY INSIGHTS CONTINUED |
|
|
|
|
|
|
Manufacturing For Oral Solid Dose Success | Adare Pharma Solutions | We provide end-to-end CDMO services for oral solid dose drugs, enabling efficient development, manufacturing, and packaging with advanced technologies and global scale. |
|
|
Comprehensive Regulatory Support | Douglas CDMO | Review our expertise across a wide range of global markets. Our experience in securing regulatory approvals and navigating market challenges positions us as a trusted partner. |
|
|
|
OUTSOURCED PHARMA CAPABILITIES UPDATE |
|
|
|
CDMOs in biologics, cell and gene, and small molecule share their capabilities and available capabilities. See for yourself why this virtual event has become a wildly popular resource to identify options for your development and manufacturing needs. |
|
|
| Connect With Outsourced Pharma: |
|
|
|
